In summary, the results of this study show that the expression levels of PD-1 on peripheral blood CD4+ T cells are helpful for disease staging in cHL patients, while dynamic detection of sPD-L1 helps evaluate the efficacy of cHL patients. This evidence concerns the gene PDCD1 and classic Hodgkin lymphoma.